SynthesisCancer medicine2025
Prognostic Factors in Newly Diagnosed High-Grade Osteosarcoma-A Systematic Review.
Synthesis in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Factors in Newly Diagnosed High-Grade Osteosarcoma-A Systematic Review.Cancer medicine · 2025Pooled it
- Human biomarker navigator.iMeta · 2026Review
- Paediatric therapeutic development workshop on osteosarcoma.British journal of cancer · 2026Review
- Diagnostic Intervals in Children, Adolescents and Young Adults with Primary Bone Sarcoma: A Systematic Review.Cancers · 2026Review
- Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting.Biomolecules · 2026Review
- Multiparametric MRI biomarkers in pediatric osteosarcoma: associations of ADC, necrosis, and tumor volume with histologic and clinical outcomes in a retrospective cohort study.Pediatric radiology · 2026Article
- Increasing survival disparity between children, adolescents, and young adults with osteosarcoma or Ewing sarcoma of bone from 1990 to 2024: a population-based cohort study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials.Cancer research communications · 2026Article
- Time-dependent evolution of osteosarcoma recurrence risk across clinical risk stratification and its prognostic value.American journal of cancer research · 2026Article
- Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications.Biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPretreatment prognostic factors in newly diagnosed osteosarcoma are important for clinical management and stratifying patients in clinical trials. Such factors include the presence of metastases, primary tumor size, and site. Factors surrounded by controversy include pathological fracture, histologic subtype, and P-glycoprotein expression. No prognostic tumor biomarker has been established. We performed a systematic review with the aim to compile available evidence for pretreatment prognostic factors and define optimal cut-off values for patient stratification or further validation in the upcoming European FOSTER-CabOS trial.
methodsPredefined search terms were used to search PubMed, Web-of-science, and Embase for all studies investigating pretreatment prognostic factors in newly diagnosed osteosarcoma patients published 2000-2023. After applying strict inclusion and exclusion criteria, 49 papers were included.
resultsWe found 14 factors investigated in at least two separate studies or in a single study using one discovery and at least one validation cohort.
conclusionsWe confirmed the prognostic value of patient age, presence of metastasis, tumor size, and site (axial vs. appendicular). Future studies of these factors should focus on specific patient populations and defining optimal cut-off values. Although serum level of alkaline phosphatase and lactate dehydrogenase were associated with outcome, it remains unclear if they are independent of other prognostic factors. The prognostic value remains unclear for sex, pathological fracture, histologic subtype, and P-glycoprotein expression. We could not establish any new prognostic biomarker. However, circulating tumor DNA in plasma and the G1/G2 RNA signature in diagnostic tumor biopsies show promise and will be further validated in the upcoming FOSTER-CabOS trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.